Fleur M. Ferguson - Publications

Affiliations: 
University of California, San Diego, La Jolla, CA 
Area:
Chemical Biology

32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Tao AJ, Jiang J, Gadbois GE, Goyal P, Boyle BT, Mumby EJ, Myers SA, English JG, Ferguson FM. A biotin targeting chimera (BioTAC) system to map small molecule interactomes in situ. Nature Communications. 14: 8016. PMID 38049406 DOI: 10.1038/s41467-023-43507-5  0.328
2023 Tao AJ, Jiang J, Gadbois GE, Goyal P, Boyle BT, Mumby EJ, Myers SA, English JG, Ferguson FM. A Biotin Targeting Chimera (BioTAC) System to Map Small Molecule Interactomes . Biorxiv : the Preprint Server For Biology. PMID 37662262 DOI: 10.1101/2023.08.21.554211  0.398
2023 Fan AT, Boyle BT, Ferguson FM. A new avenue for molecular glues: Rapid discovery of a NFKB1 degrader. Cell Chemical Biology. 30: 340-342. PMID 37084716 DOI: 10.1016/j.chembiol.2023.04.002  0.346
2022 Tran NL, Leconte GA, Ferguson FM. Targeted Protein Degradation: Design Considerations for PROTAC Development. Current Protocols. 2: e611. PMID 36469581 DOI: 10.1002/cpz1.611  0.816
2022 Silva MC, Nandi G, Donovan KA, Cai Q, Berry BC, Nowak RP, Fischer ES, Gray NS, Ferguson FM, Haggarty SJ. Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy. Frontiers in Cellular Neuroscience. 16: 801179. PMID 35317195 DOI: 10.3389/fncel.2022.801179  0.68
2022 Tao AJ, Gadbois GE, Buczynski SA, Ferguson FM. Targeted protein degradation: Emerging concepts and protein state-specific targeting principles. Current Opinion in Chemical Biology. 67: 102114. PMID 35042023 DOI: 10.1016/j.cbpa.2021.102114  0.766
2021 Seong BKA, Dharia NV, Lin S, Donovan KA, Chong S, Robichaud A, Conway A, Hamze A, Ross L, Alexe G, Adane B, Nabet B, Ferguson FM, Stolte B, Wang EJ, et al. TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma. Cancer Cell. PMID 34329586 DOI: 10.1016/j.ccell.2021.07.003  0.551
2021 Carli ALE, Afshar-Sterle S, Rai A, Fang H, O'Keefe R, Tse J, Ferguson FM, Gray NS, Ernst M, Greening DW, Buchert M. Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells. Proteomics. e2000098. PMID 33991177 DOI: 10.1002/pmic.202000098  0.486
2021 Jiang B, Jiang J, Kaltheuner IH, Iniguez AB, Anand K, Ferguson FM, Ficarro SB, Seong BKA, Greifenberg AK, Dust S, Kwiatkowski NP, Marto JA, Stegmaier K, Zhang T, Geyer M, et al. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. European Journal of Medicinal Chemistry. 221: 113481. PMID 33945934 DOI: 10.1016/j.ejmech.2021.113481  0.813
2020 Donovan KA, Ferguson FM, Bushman JW, Eleuteri NA, Bhunia D, Ryu S, Tan L, Shi K, Yue H, Liu X, Dobrovolsky D, Jiang B, Wang J, Hao M, You I, et al. Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell. PMID 33275901 DOI: 10.1016/j.cell.2020.10.038  0.757
2020 Nabet B, Ferguson FM, Seong BKA, Kuljanin M, Leggett AL, Mohardt ML, Robichaud A, Conway AS, Buckley DL, Mancias JD, Bradner JE, Stegmaier K, Gray NS. Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nature Communications. 11: 4687. PMID 32948771 DOI: 10.1038/S41467-020-18377-W  0.603
2020 Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S, Westover KD, Gray NS. Correction to "Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6-benzo[]pyrimido[5,4-][1,4]diazepin-6-one Scaffold". Journal of Medicinal Chemistry. PMID 32790356 DOI: 10.1021/acs.jmedchem.0c01338  0.766
2020 Liu Y, Ferguson FM, Li L, Kuljanin M, Mills CE, Subramanian K, Harshbarger W, Gondi S, Wang J, Sorger PK, Mancias JD, Gray NS, Westover KD. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell Chemical Biology. PMID 32755567 DOI: 10.1016/J.Chembiol.2020.07.011  0.711
2020 Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S, Westover KD, Gray NS. Synthesis and structure activity relationships of DCLK1 kinase inhibitors based on a 5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one scaffold. Journal of Medicinal Chemistry. PMID 32530623 DOI: 10.1021/Acs.Jmedchem.0C00596  0.782
2020 Jaeger MG, Schwalb B, Mackowiak SD, Velychko T, Hanzl A, Imrichova H, Brand M, Agerer B, Chorn S, Nabet B, Ferguson FM, Müller AC, Bergthaler A, Gray NS, Bradner JE, et al. Selective Mediator dependence of cell-type-specifying transcription. Nature Genetics. PMID 32483291 DOI: 10.1038/S41588-020-0635-0  0.446
2020 Manz TD, Sivakumaren SC, Ferguson FM, Zhang T, Yasgar A, Seo HS, Ficarro SB, Card JD, Shim H, Miduturu CV, Simeonov A, Shen M, Marto JA, Dhe-Paganon S, Hall MD, et al. Discovery and Structure-Activity Relationship Study of (Z)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. Journal of Medicinal Chemistry. PMID 32298120 DOI: 10.1021/Acs.Jmedchem.0C00227  0.836
2020 Ferguson FM, Nabet B, Raghavan S, Liu Y, Leggett AL, Kuljanin M, Kalekar RL, Yang A, He S, Wang J, Ng RWS, Sulahian R, Li L, Poulin EJ, Huang L, et al. Discovery of a selective inhibitor of doublecortin like kinase 1. Nature Chemical Biology. PMID 32251410 DOI: 10.1038/S41589-020-0506-0  0.783
2020 Manz TD, Sivakumaren SC, Yasgar A, Hall MD, Davis MI, Seo HS, Card JD, Ficarro SB, Shim H, Marto JA, Dhe-Paganon S, Sasaki AT, Boxer MB, Simeonov A, Cantley LC, ... ... Ferguson FM, et al. Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. Acs Medicinal Chemistry Letters. 11: 346-352. PMID 32184968 DOI: 10.1021/Acsmedchemlett.9B00402  0.831
2020 Sivakumaren SC, Shim H, Zhang T, Ferguson FM, Lundquist MR, Browne CM, Seo HS, Paddock MN, Manz TD, Jiang B, Hao MF, Krishnan P, Wang DG, Yang TJ, Kwiatkowski NP, et al. Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. Cell Chemical Biology. PMID 32130941 DOI: 10.1016/J.Chembiol.2020.02.003  0.784
2019 Remillard D, Buckley DL, Seo HS, Ferguson FM, Dhe-Paganon S, Bradner JE, Gray NS. Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold. Acs Medicinal Chemistry Letters. 10: 1443-1449. PMID 31620231 DOI: 10.1021/Acsmedchemlett.9B00243  0.654
2019 Ferguson FM, Doctor ZM, Ficarro SB, Marto JA, Kim ND, Sim T, Gray NS. Synthesis and structure activity relationships of a series of 4-amino-1H-pyrazoles as covalent inhibitors of CDK14. Bioorganic & Medicinal Chemistry Letters. PMID 31175010 DOI: 10.1016/J.Bmcl.2019.05.024  0.825
2019 Ferguson FM, Doctor ZM, Ficarro SB, Browne CM, Marto JA, Johnson JL, Yaron TM, Cantley LC, Kim ND, Sim T, Berberich MJ, Kalocsay M, Sorger PK, Gray NS. Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity. Cell Chemical Biology. PMID 30930164 DOI: 10.1016/J.Chembiol.2019.02.015  0.827
2019 Silva MC, Ferguson FM, Cai Q, Donovan KA, Nandi G, Patnaik D, Zhang T, Huang HT, Lucente DE, Dickerson BC, Mitchison TJ, Fischer ES, Gray NS, Haggarty SJ. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. Elife. 8. PMID 30907729 DOI: 10.7554/Elife.45457  0.682
2019 Silva MC, Ferguson FM, Cai Q, Donovan KA, Nandi G, Patnaik D, Zhang T, Huang H, Lucente DE, Dickerson BC, Mitchison TJ, Fischer ES, Gray NS, Haggarty SJ. Author response: Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models Elife. DOI: 10.7554/Elife.45457.037  0.337
2018 Wang J, Erazo T, Ferguson FM, Buckley DL, Gomez N, Muñoz-Guardiola P, Diéguez-Martínez N, Deng X, Hao M, Massefski W, Fedorov O, Offei-Addo NK, Park PM, Dai L, DiBona A, et al. Structural and atropisomeric factors governing the selectivity of pyrimido-benzodiazipinones as inhibitors of kinases and bromodomains. Acs Chemical Biology. PMID 30102854 DOI: 10.2210/Pdb6Cd5/Pdb  0.805
2018 Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nature Reviews. Drug Discovery. PMID 29545548 DOI: 10.1038/Nrd.2018.21  0.697
2017 Ferguson FM, Doctor ZM, Chaikuad A, Sim T, Kim ND, Knapp S, Gray NS. Characterization of a highly selective inhibitor of the Aurora kinases. Bioorganic & Medicinal Chemistry Letters. PMID 28818446 DOI: 10.1016/J.Bmcl.2017.08.016  0.848
2016 Ferguson FM, Ni J, Zhang T, Tesar B, Sim T, Kim ND, Deng X, Brown JR, Zhao JJ, Gray NS. Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors. Acs Medicinal Chemistry Letters. 7: 908-912. PMID 27774127 DOI: 10.1021/Acsmedchemlett.6B00209  0.71
2015 Tallant C, Valentini E, Fedorov O, Overvoorde L, Ferguson FM, Filippakopoulos P, Svergun DI, Knapp S, Ciulli A. Molecular basis of histone tail recognition by human TIP5 PHD finger and bromodomain of the chromatin remodeling complex NoRC. Structure (London, England : 1993). 23: 80-92. PMID 25533489 DOI: 10.1016/J.Str.2014.10.017  0.688
2014 Baud MG, Lin-Shiao E, Cardote T, Tallant C, Pschibul A, Chan KH, Zengerle M, Garcia JR, Kwan TT, Ferguson FM, Ciulli A. Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science (New York, N.Y.). 346: 638-41. PMID 25323695 DOI: 10.1126/Science.1249830  0.815
2014 Ferguson FM, Dias DM, Rodrigues JP, Wienk H, Boelens R, Bonvin AM, Abell C, Ciulli A. Binding hotspots of BAZ2B bromodomain: Histone interaction revealed by solution NMR driven docking. Biochemistry. 53: 6706-16. PMID 25266743 DOI: 10.1021/Bi500909D  0.785
2013 Ferguson FM, Fedorov O, Chaikuad A, Philpott M, Muniz JR, Felletar I, von Delft F, Heightman T, Knapp S, Abell C, Ciulli A. Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain. Journal of Medicinal Chemistry. 56: 10183-7. PMID 24304323 DOI: 10.1021/Jm401582C  0.818
Show low-probability matches.